Business
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"text","content":"TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').","length":433,"tagName":"p"},{"type":"image","alt":"Galmed_Pharmaceuticals_Logo","displaySize":"","headline":null,"caption":"Galmed_Pharmaceuticals_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rkpv_HpbOjVKPN_v6KG17Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0bd7ffdcf08721d90a3bcb5658c1e61e","width":400,"height":95}}},{"type":"text","content":"The report is available on the SEC's website, at www.sec.gov and Galmed's Investor Relations website, at https://galmedpharma.investorroom.com/sec-filings.","length":168,"tagName":"p"},{"type":"text","content":"Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed's Investor Relations Department at [email protected].","length":231,"tagName":"p"},{"type":"text","content":"About Galmed Pharmaceuticals Ltd.","length":33,"tagName":"p"},{"type":"text","content":"We are a clinical stage biopharmaceutical company focused on the development of Aramchol for oncological indications outside of liver disease. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.","length":418,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements:","length":27,"tagName":"p"},{"type":"text","content":"Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet o...